Critical appraisal of the role of everolimus in advanced neuroendocrine tumors of pancreatic origin

References

• Modlin I, Shapiro MD, Kidd M, Eick G. Siegfried Oberndorfer and the evolution of carcinoid disease. Arch Surg. 2007;142:187–197.
   PubMedGoogle Scholar
• Hemminli K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer. 2001;92:2204–2210.
   Web of Science ®Google Scholar
• Yao C, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35.825 cases in the United States. J Clin Oncol. 2008;26:3063–3072.
   PubMed Web of Science ®Google Scholar
• Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–959.
   PubMed Web of Science ®Google Scholar
• Levi F, Te V-C, Randimbison L, Rindi G, La Vecchia C. Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974–1997. Br J Cancer. 2000;83:952–955.
   PubMed Web of Science ®Google Scholar
• García-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroen- teropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010;21:1794–1803.
   PubMed Web of Science ®Google Scholar
• Kouvaraki M, Ajani J, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22:4762–4771.
   PubMed Web of Science ®Google Scholar
• ENETS 2011. Consensus guidelines for the management of patients with digestive neuroendocrine tumors. Neuroendocrinology. 2012;95:67–178.
   Web of Science ®Google Scholar
• Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39:735–752.
   PubMed Web of Science ®Google Scholar
• Grozinsky-Glasberg, Franchi G, Teng M, et al. Octeotride and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumor cell line. Neuroendocrinology. 2008;87:168–181.
   PubMed Web of Science ®Google Scholar
• Rinke A, Müller H, Schade-Brittinger, et al. Placebo-controlled, doubleblind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–4663.
   PubMed Web of Science ®Google Scholar
• Clinical Trials. gov. US National Institutes of Health. Available from: http://www.clinicaltrials.gov. Accessed on May 30, 2012.
   Google Scholar
• Capdevila J, Tabernero J. A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors. Cancer Discov. 2011;1:213–221.
   Web of Science ®Google Scholar
• Capdevila J, Salazar R, Halperin I, Abad A, Yao JC. Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors. Cancer Metastasis Rev. 2011;30:27–34.
   Web of Science ®Google Scholar
• Pópulo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci. 2012;13:1886–1918.
   PubMed Web of Science ®Google Scholar
• Albanell J, Dalmases A, Rovira A, et al. mTOR signalling in human cancer. Clin Transl Oncol. 2007;9:484–493.
   PubMed Web of Science ®Google Scholar
• O’Donnell A, Faivre S, Burris HA, III, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol. 2008;26:1588–1595.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Rojo F, Calvo E, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a Phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol. 2008;26:1603–1610.
   PubMed Web of Science ®Google Scholar
• Chiu C, Nozawa H, Hanahan D. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclini- cal model of pancreatic neuroendocrine carcinogenesis. J Clin Oncol. 2010;28:4425–4433.
   PubMed Web of Science ®Google Scholar
• Hörsch D, Tielke S, Schrader J. Expression and activation of mTOR in neuroendocrine tumors: Effect of mTor inhibition by RAD001 upon growth, cell cycle regulation and signaling in neuroendocrine cell lines. J Clin Oncol. 2007;25 Suppl:Abstr 10570.
   Web of Science ®Google Scholar
• Zitzmann K, De Toni EN, Brand S, et al. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology. 2007;85:54–60.
   PubMed Web of Science ®Google Scholar
• Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN 1 and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331:1199–1203.
   PubMed Web of Science ®Google Scholar
• Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT mTOR pathway. J Clin Oncol. 2010;28:245–255.
   PubMed Web of Science ®Google Scholar
• Yao J, Shah M, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–523.
   PubMed Web of Science ®Google Scholar
• Duran I, Kortmansky J, Singh D, et al. A Phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer. 2006;95:1148–1154.
   PubMed Web of Science ®Google Scholar
• Yao J, Phan A, Chang D, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a Phase II study. J Clin Oncol. 2008;26:4311^4318.
   Web of Science ®Google Scholar
• Yao J, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a Phase II trial. J Clin Oncol. 2010;28:69–76.
   PubMed Web of Science ®Google Scholar
• Shah MH, Lombard-Bohas C, Ito T, et al. Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial. J Clin Oncol. 2011;29 Suppl:4013.
   Web of Science ®Google Scholar
• O’Reilly, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66:1500–1508.
   PubMed Web of Science ®Google Scholar
• Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2007;26:1932–1940.
   PubMed Web of Science ®Google Scholar
• Hobday T, Qin R, Reidy DL, et al. Multicenter phase II trial of temsi- rolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET). J Clin Oncol. 2012;30 Suppl 4:Abstr 260.
   Google Scholar
• Capdevila J, Sevilla I, Alonso V et al. Evaluation of safety and efficacy of somatuline autogel in combination with molecular targeted therapies (MTT) in patients with neuroendocrine tumors (NETs): data from one Spanish cohort. J Clin Oncol. 2012;30 Suppl:Abstr 14671.
   Google Scholar
• Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501–513.
   PubMed Web of Science ®Google Scholar